Truffle Capital

www.truffle.com

VCMatch tracks Truffle Capital as an investor focused on Biotech, Medtech, and Healthtech companies, Seed and Series A rounds, Europe, France, and United States markets, and $5m to $15m check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$5m to $15m

Stages

Seed, Series A, Series B, Growth, Late Stage

Focus Areas

Biotech, Medtech, Healthtech

Geography

Europe, France, and United States

Investment Thesis

Truffle Capital operates as ‘More than an investor, an ecosystem’ - positioning itself as a proactive business builder that collaborates closely with world-class research centers to transform significant unmet needs into major technological advancements. The firm believes in driving creation and development of companies on their journey to becoming tomorrow’s leaders in healthcare and finance. Their philosophy emphasizes that ‘There is no major problem or issue that great science and R&D cannot address.’

Is Truffle Capital right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Truffle Capital is most relevant for founders raising Seed, Series A, and Series B rounds in Biotech, Medtech, Healthtech, and Fintech, especially across Europe, France, and United States, with public check-size signals around $5m to $15m.

Focus statement

Truffle Capital finances radical innovation in two core sectors: Life Sciences (MedTech, Biotech & BioEcoTech) and Deeptech applied to Finance (Fintech & Insurtech). They focus exclusively on breakthrough technologies that revolutionize therapeutic areas, not marginal innovations.

Value Add

Lead investor approach with board seats - 'Systematic lead investor with a seat on the board'
Company creation capability - 'We either create new companies from patent applications, or we strengthen existing companies, in the European Ecosystem'
Dual specialization across 25+ years in BioMedTech (since 2001) and 10+ years in Fintech (since 2015)
Strong exit track record: 45 exits including 15 IPOs and major acquisitions (Symetis to Boston Scientific for $435M, Vexim to Stryker for $221M)
Exclusive in-license of 19 technologies from academic institutions
ESG embedded in DNA - signatory of PRI since 2012 with formal responsible investment policy
European independent VC status with €500M AuM